On March 19, 2025 Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") reported updated data confirming efficacy of its Targeted Hyperthermia Therapy ("THT") cancer treatment in an immunotherapy resistant cancer (Press release, Sona Nanotech, MAR 19, 2025, View Source [SID1234652834]). In this follow-up data to the previously released preliminary study (see press release dated December 11, 2024), again using an industry-standard, immunotherapy resistant, CT-26 colon cancer model, Sona’s THT cancer treatment was 100% effective in activating a strong, effective immune system response. In these experiments, animals treated with a PD-1 checkpoint inhibitor, a standard of care immunotherapy, experienced no benefit with tumors growing similarly to tumors in the control group of untreated animals. However, in a new, second cohort of eight animals first treated with Sona’s THT and then treated with a PD-1 inhibitor, 100% of animals responded demonstrating near complete arrest in tumor growth in the majority of animals as highlighted by the dashed green line in Figure 1, below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sona Nanotech CMO, Dr. Carman Giacomantonio, commented, "In this study, Sona’s THT cancer treatment is clearly the difference maker in inhibiting the growth of this notoriously difficult-to-treat cancer. THT’s ability to cause the expression of new antigens causes the immune system to engage, which we show permits immunotherapies to work better, making THT a powerful potential immunotherapy in its own right."

Sona Nanotech CEO, David Regan, commented, "While still an early preclinical study, we are nonetheless very excited to see the repeatability of our earlier successful preclinical colorectal study results. This data gives us additional confidence as to THT’s ability to enhance the response rates of immunotherapies used in humans, which we expect to be able to assess shortly in our first-in-human early feasibility study."

Further data from this experiment can be found in the Company’s updated corporate presentation, which can be accessed in the Investor Section of its website.

Sona’s THT cancer treatment uses the Company’s patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and stimulating the immune system, which has been shown in preclinical studies to enhance the response rates of two different immunotherapy drugs, IL-2 and PD-1.